IL-11Rα is an important
cytokine receptor that links oxidative stress and compensatory proliferation. Mounting evidence has demonstrated that IL-11Rα regulates autoimmune
demyelination and the invasion and proliferation of
cancer cells, making it an important therapeutic target for
molecular targeted therapy. Moreover, overexpression of IL-11Rα indicates a poor long-term prognosis in
cancer patients. However, the expression status and its potential as a
biomarker for diagnosis,
tumor imaging, and prognosis in
osteosarcoma remain to be determined. We report here that IL-11Rα is highly expressed in
osteosarcoma and near-infrared (NIR)-labeled IL-11Rα imaging agent could detect
osteosarcoma in mouse
tumor xenografts. In a panel of human
osteosarcoma specimens, IL-11Rα
protein was positively stained in most cases by immunohistochemistry. Western blot analysis and flow cytometry showed that IL-11Rα was overexpressed in
osteosarcoma SOSP-9607 cells. Cell-binding assay demonstrated specific binding of the IL-11Rα targeted imaging agent to
osteosarcoma SOSP-9607 cells in vitro. In addition, administration of an IL-11Rα targeted imaging agent in a nude mice orthotopic model resulted in selective accumulation of NIR fluorescent signals in the bone
tumor as well as several metabolic organs. These results indicate that IL-11Rα is a potential target for the development of
molecular targeted therapy and noninvasive
tumor imaging in human
osteosarcoma. Furthermore, NIR-labeled IL-11Rα imaging agent is a promising lead for the development of a
tumor in vivo imaging method at the molecular level in the management of human
osteosarcoma.